Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linking inflammation to cell cycle progression.

Gustavo Baldassarre1, Milena S Nicoloso, Monica Schiappacassi

  • 1Divisione di Oncologia Sperimentale 2, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS Aviano 33081, Italy. gbaldassarre@cro.it

Current Pharmaceutical Design
|May 12, 2004
PubMed
Summary

Chronic inflammation increases oxidant levels, raising gastrointestinal cancer risk. Anti-inflammatory and antioxidant therapies may inhibit cancer development by modulating cell cycle regulation and inflammatory pathways.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct 2-phenylimidazo[1,2-<i>a</i>]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

iScience·2026
Same author

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

BRAF class II-III mutations in NSCLC: a single center experience.

Frontiers in oncology·2026
Same author

Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer.

Cell death & disease·2026
Same author

Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials.

Cancer treatment reviews·2026
Same author

Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.

Breast (Edinburgh, Scotland)·2026

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Gastrointestinal cancer risk correlates with elevated oxidants, potentially due to impaired epithelial barrier function and inflammation.
  • Chronic inflammatory diseases are established risk factors for cancer, while anti-inflammatory and antioxidant agents show inhibitory effects in models and humans.

Purpose of the Study:

  • To elucidate the molecular mechanisms linking inflammation, oxidative stress, and cellular transformation in gastrointestinal cancers.
  • To understand the role of Cyclooxygenase-2 (COX-2) and Reactive Oxygen Intermediates (ROI) in inflammation-driven carcinogenesis.
  • To investigate how cell cycle regulatory proteins are affected by inflammation and therapeutic interventions.

Main Methods:

  • Review of epidemiological observations and molecular mechanisms.

Related Experiment Videos

  • Analysis of the roles of Cyclooxygenase-2 (COX-2) and Reactive Oxygen Intermediates (ROI) in cellular transformation.
  • Examination of the impact of inflammation and therapeutic agents on cell cycle checkpoint proteins.

    • Main Results:

    • Activation of COX-2 and production of ROI are key molecular events linking inflammation to cellular transformation.
    • Uncontrolled cell proliferation in cancer is associated with deregulation of cell cycle checkpoint proteins.
    • Anti-inflammatory and antioxidant agents can influence the expression and function of cell cycle regulators.

    Conclusions:

    • Understanding the interplay between chronic inflammation, oxidative stress, and cell cycle deregulation is crucial for developing targeted cancer therapies.
    • Targeting inflammatory pathways and oxidative stress may offer novel strategies for preventing or treating gastrointestinal cancers.
    • Further research into the genetic and epigenetic changes driving malignant transformation is needed for improved treatment strategies.